



TMCi Accelerator for Cancer Therapeutics

GCC Foundations of Cancer Therapeutics



TMC*i*



Texas is Home to the World's Largest Medical Center and World-Class Cancer Institutes

THE UNIVERSITY OF TEXAS
~~MD Anderson~~
Cancer Center

Baylor
College of
Medicine

 UT Health
San Antonio

 Health

HOUSTON
Methodist[®]
LEADING MEDICINE

 UTHealth[™]
The University of Texas
Health Science Center at Houston

UTSouthwestern
Medical Center

 TEXAS
The University of Texas at Austin


HEALTH SCIENCE CENTER
TEXAS A & M UNIVERSITY

 TEXAS TECH
UNIVERSITY.


UNIVERSITY of
HOUSTON

TMCⁱ

There is a Significant Missed Opportunity in Translating Texas Cancer Research to Commercial Ventures and the Clinic

2019 Research Commercialization Gap

VC/Research dollar ratio gap to national average, weighted by overall NCI research dollars



Notable Recent Exits Based On Texas Technologies



IPO 2020
\$150M, \$571M
mkt cap



IPO 2020
\$276M, \$2.5B
mkt cap



Acquired 2019
Merck, \$2.2B

Texas research is **valuable**, but each opportunity has a substantial geographic barrier

TMCi Accelerator

- Prepares companies for success in every stage of growth by creating a **solid foundation**
- Supports a **critical stage** of company formation and launch
- **Brings together** founders, talent, knowledge, and investors



Team



Thomas Luby, PhD
Director, TMC Innovation



Diana Rhie
Senior Manager,
Strategy and Operations



Ashley Francis, MPH
Program Manager



Suzanne Tomlinson, PhD
Gulf Coast Consortia
Director



Sarah Hein, PhD
Entrepreneur-in-Residence



Enrique Gomez, MSc
Entrepreneur-in-Residence



Amit Gupta, PhD
Computational Chemist



Emily Reiser, PhD
Senior Manager,
Community Engagement



Stan Watowich, PhD
Professor at UTMB and
CEO of Ridgeline
Therapeutics

Executive Advisory Committee



Dan Watkins, PhD
Managing Director
Mercury Fund



Dan Hargrove
Chief Development Officer
Cancer Insight



Annemarie Moseley
Chief Medical Officer
ImmunoGenesis




Ann Tanabe
Chief Executive Officer
BioHouston



Casey Cunningham
Chief Scientific Officer
Sante Ventures

Our Guide Star

- Provide access to key talent, advisor, and strategic consultant **resources** to build **credible plans**
- To **support product development** through computational chemistry and CPRIT core network access
- To **support fundraising efforts** through both non-dilutive grant applications and venture capital raises



Accelerator Structure and Benefits

2022 Accelerator Schedule

January	Bootcamp
February – July	Bimonthly in-person curriculum
September	TMCi Accelerator for cancer therapeutics SUMMIT

Benefits

- Expert consultant access
- Executive mentor advisory sessions
- Grant writing support for SBIR and CPRIT applications
- Investor introductions
- GCC CPRIT core access

All benefits to participants are 100% Free

2021 Inaugural Cohort

Drug Platform



Immunotherapy



Cell Therapy



Targeted Therapy



Cancer Pain






Common Questions



How Do I Know If I Should Be Thinking About This For Me?

TMC^{*i*}





How Do I Find the Best Path for My Technology?

TMC^{*i*}



Why Don't Investors or Partners Like This Project?

TMC^{*i*}



How Do I Put Together the Right Team?

TMC*i*



What Makes A Successful Founder?


TMC*i*





What Has Been Most Surprising About This Year?

TMC^{*i*}





Applications Open September 9th

- Apply on the Accelerator website:
<https://www.tmc.edu/innovation/accelerator-cancer/>
- Office hours available for project feedback and additional program information



Contact Us

Accelerator for cancer therapeutics

act@tmc.edu

TMC*i*

